Competing interests: HMcS is supported by a diverse group of funders, including the Wellcome Trust, The Bill and Melinda Gates Foundation, Aeras, and the European Commission, to develop new TB vaccines. MVA85A was developed in her laboratory. AH is director of the Jenner Institute, where MVA85A was developed, and has received grant income from a large number of funders for vaccine development, especially against malaria. He is a co-inventor of several vaccine technologies licensed through Oxford University Innovations. MH has received support through institutional grants to the University of Cape Town from multiple funders, including Aeras and the Wellcome Trust, for clinical trials of several TB vaccine candidates including MVA85A. MT has worked on multiple TB vaccine projects funded by Aeras and the Wellcome Trust including MVA85A projects. She has previously received two Wellcome Trust International Engagement grants. JS was the general manager of the Oxford Emergent TB Consortium, the commercial licensor of the MVA858A vaccine and part funder of the MVA85A trial. She is currently CEO of Aeras, one of the funders and sponsor of the MVA85A trial. AG is currently the chief medical officer for Aeras, which was one of the funders and sponsor of the MVA85A trial.